

References

REFERENCES

Ablin, R.J.; Soanes, W.A.; Bronson, P. et al. (1970):

Precipitating antigens of the normal human prostate. J. Reported Fertility., 22: 573 quoted from *Kozłowski, J.M. and Grayhack, J.T. (2002):* Carcinoma of the prostate. In: Gillenwater J.Y, Grayhack, J.T.; Howards, S.S. and Mitchell, M.E. (Eds). Adults and Pediatric Urology, 4th edition Lippincott Williams and Wilkins.

Aksoy, Y.; Oral, A.; Aksoy, H.; Demirel, A. and Akay, F. (2003):

PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Ann. Clin. Lab. Sci., 33 (33): 320-323.

American Medical Association (2001):

Report 9 of the Council on Scientific Affairs (A-OO). Screening and Early detection of prostate cancer. June 2001. Web site , <http://www.ama-assn.org/ama/pub/article/2036-2928.htm/>. Accessed March 01, 2001.

American Urological Association (2000):

Prostate-specific antigen (PSA) best practice policy.American Urological Association(AUA),Clinical guidelines.Oncology,14: 267.

Andersson, S.O.; Baron, J.; Wolk, A. et al. (1995):

Early life risk factors for prostate cancer: A population-based case-control study in Sweeden. Cancer Epidemiol. Biom. Prev., 4: 187-192.

Andersson S.O, Wolk A, Bergstrom R, et al.(1996):

Energy, nutrient intake and prostate cancer risk: A population-based case-control study in Sweden. Int J Cancer;68:716.

Andersson, S.O.; Wolk, A.; Bergstrom, R. et al. (1997):

Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction worker. J. Nalt. Cancer Inst.,89: 385.

Andriole, G.L.; Levine, D.L.; Crawford, E.D. et al. (2005):

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screening round of a randomized trial. *J. Natl. Can. Inst.*, 97 (6): 433-438.

Applewhite, J.C.; Matlaga, B.R.; McCullough, D.L. and Hall, M.C. (2001):

Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. *Cancer Control*, 8: 141-150.

Armbruster, D.A. (1993):

Prostate specific antigen: Biochemistry, analytic methods, and clinical application. *Clin. Chem.*, 39: 181.

Aronson, W.J. and Freeland, S.J. (2000):

Can we lower the mortality of black men with prostate cancer. (editorial). *J. Urol.*, 163: 150.

Astral-di, A. (1937):

Diagnosis of cancer of the prostate: biopsy by rectal route. *Urol. Cutan. Rev.*, 189: 153-156. quoted from Applewhite, J.C.; Matlaag, B.R.; McCullough, D.L. and Hall, M.C. (2001): Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. *Cancer Control*, 8: 141-150.

Aus, G.; Bergdahl, S.; Frosing, R. et al. (1996):

Reference range of prostate-specific antigen after transurethral resection of the prostate. *Urology*, 45: 529.

Babaian, R.J. (2000):

Extended field prostate biopsy enhances cancer detection. *Urology*, 57: 1117-1120.

Babaian, R.J.; Dinney, C.P.N.; Ramirez, E.L. and Evan, R.B. (1993):

Diagnostic testing for prostate cancer detection: less is best. *Urology*, 41: 421-5.

Barrett-Connor, E.; Garland, C.; McPhillips, J.B. et al. (1990):

A prospective population-based study of androstendione, estrogen and prostate cancer. *Cancer Res.*, 50: 169.

- Bartsch, G.; Horninger, W.; Klocker, H. et al. (2000):**
Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. J. Urol., 163 (Suppl. 4): 88.
- Bazinet, M.; Meshref, A.W.; Trudel, C. et al. (1994):**
Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology;43:44.
- Benaim, E.A.; Pace, C.M.; Lam, P.M. and Roehrborn, C.G. (2002):**
Nadvi P-SA as a progression to androgen-independent prostate cancer. Urology, 59: 73.
- Benson, M.C. (1994):**
Editorial: Prostate specific antigen. J Urol;152:2046.
- Benson, M.C.; Whang, I.S.; Pantuck, A. et al. (1992):**
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and cancer. J Urol;147:815.
- Berenguer, A.; Lujan, M.; Santonja, C. And Pascuala, T. (2003):**
The spanish contribution to the European Randomized Study of Screening for prostate cancer. BJU International, 92, Supplement 2: 33-38.
- Bjork, T.; Bjartell, A.; Abrahmsson, P.A. et al. (1994):**
Alpha1-anti-chemotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urol., 43: 247.
- Blot, W.J.; Chow, W.H. and McLaughlin, J.K. (1996):**
Tea and cancer: a review of the epidemiologic evidence. Eur. J. Cancer Prev;5:425.
- Bocchicchio, T. and Fair, W.R. (1999):**
Nutrition and cancer prostate. AUA updated series; 18, Lesson 38, : 298-303.
- Bostwick, D.G. (1994):**
Grading prostate cancer.
Am. J. Clin. Pathol ., 102 (Suppl. 1): s38-56.

Bostwick, D.G. (1999):

Prostate intraepithelial neoplasia. In Kaisary AV, Murphy GP, Denis L, Griffiths K eds. Text book of prostate cancer pathology, diagnosis and treatment. London: Martin Dunitz Ltd: 35-50. quoted from **(The Prognostic Significance of CD44, p21 and MIB-1 in Cancer Prostate)** MD thesis by Nashwa M. Emara, Pathology Department, Benha Faculty of Medicine. 2003

Boyle, D.; Severi, G. and Giles, G. (2003):

The epidemiology of prostate cancer. *Urol Clin N Am.*; 30: 209-217.

Brawer, M.K. (1999):

Prostate-specific antigen: current status.
CA Cancer J. Clin. 49: 264.

Brawer, M.K. (2000):

Screening for prostate cancer. *Semin. Surg. Oncol.*, 18: 29-36.

Brawer, M.K.; Smith, D.; Ratcliff, T. et al. (1992):

Screening for prostatic carcinoma with prostate-specific antigen.
J. Urol., 147: 841-845.

Brawer, M.K.; Aramburu, E.A.G.; Chen, G.L. et al. (1993):

The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostate carcinoma. *J. Urol.*, 150: 369.

Brawer, M.K.; Benson, M.C.; Djavan, B. et al. (1999):

Prostate serum marker. In: Murphy, G.; Khoury, S.; Partin, A. and Denis, L. (eds): Prostate cancer (2nd International Consultation on Prostate Cancer. J. 27-29, Paris, Health Publication. Ltd. ISBN 1, 89845235 0.

Brawley, O.W.; Knopf, K. and Merrill, R. (1998):

The epidemiology of prostate cancer part I: descriptive epidemiology. *Semin. Urol. Oncol.*, 16: 187-192.

Brett, T.D. (1998):

An analysis of digital rectal examination and serum-prostate-specific antigen in the early detection of prostate cancer in general practice. *Family Practice*, 15 (8): 529-533.

Bretton, P.R. (1994):

Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. *South Med. J.*, 87: 720-723.

Brooks, J.D. (2002):

Anatomy of the lower urinary tract and male genitalia, In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), *Campbell's Urology*, 8th ed. Saunders Company

Budnick, L.D. (1992):

Statistics: In: Cassens BJ (ed), *preventive medicine and public health* 2nd edition, National Medical series from Williams and Wilkins.

Candas, B.; Cusan, L.; Gomez, J.L. et al. (2000):

Evaluation of prostatic specific antigen and digital rectal examination as screening test for prostate cancer. *Prostate*, 45 (1): 19-35.

Carlson, G.D.; Calvanese, C.B. and Childs, S. (1998):

The appropriate lower limit for the percent free prostate-specific antigen reflex range. *Urology*, 52 (3): 450-454

Carruba, G.; Miceli, M.D.; Comito, L.; Farruggio, R.; Sorci, C.M. et al. (1996):

Multiple estrogen function in human prostate cancer cells. *Annals NY. Acad. Sci.*, 784: 70-84. Quoted from *Stanford, J.L.; Damber, J.E.; Fair, W.R. et al. (1999):* Epidemiology of prostate cancer. In: Murphy, G.; Khoury, S.; Partin, A. and Denis, L. (eds): *Prostate cancer* (2nd International Consultation on Prostate Cancer. June. 27-29, Paris, Health Publication. Ltd. ISBN 1 89845235 0.

Carter, H.B. and Partin, A.W. (2002):

Diagnosis and staging of prostate cancer. In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), Campbell's Urology, 8th ed. Saunders Company.

Carter, B.S.; Beaty, T.H.; Steinberg, O.D.; Childs, B. and Walsh, P.C. (1992a):

Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci., USA, 89: 3367 Quoted from **Reiter, R.E. and Dekernion, J. (2002):** Epidemiology, etiology and prevention of prostate cancer. In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), Campbell's Urology, 8th ed. Saunders Company.

Carter, H.B.; Pearson, J.D.; Metter, J.E. et al (1992b):

Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA;267:2215.

Carter, B.S.; Bova, G.S.; Beaty, T.H. et al. (1993):

Hereditary prostate cancer: epidemiologic and clinical features. J. Urol., 150: 797.

Carter, H.B.; Epstein, J.I.; Chan, D.W. et al. (1997):

Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA;277:1456.

Catalona, W.J.; Smith, D.S.; Ratliff, T.L. et al. (1993):

Free PSA, percent free PSA, and PSA density: predictors of prostate cancer. J. Urol., 150: 1214-1218.

Catalona, W.J.; Smith, D.S.; Landrum, A.L. et al. (1995): Clinical features of prostate cancer detected in a trial of 6650 men. J. Urol., 154: 1283-1290.

Catalona, W.J.; Smith, D.S. and Ornstein, D.K. (1997):

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostatic examination. Enhancement of specificity with free PSA measurements. JAMA, 277 (18): 1452-1455.

- Catalona, W.J.; Partin, A.W.; Slawin, K.M. et al. (1998):**
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. *JAMA*, 279 (19): 1542-1547.
- Cerhan, J.R.; Torner, J.C.; Lynch, C.F. et al. (1997):**
Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). *Cancer Control*, 8: 229-238.
- Chaisiri, N. and Pierrepont, G.G. (1980):**
Examination of the distribution of estrogen receptor between stromal and epithelial compartment of the canine prostate. *Prostate*, 1: 357-366. Quoted from *Stanford, J.L.; Damber, J.E.; Fair, W.R. et al. (1999):* Epidemiology of prostate cancer. In: Murphy, G.; Khoury, S.; Partin, A. and Denis, L. (eds): *Prostate cancer* (2nd International Consultation on Prostate Cancer. June. 27-29, Paris, Health Publication. Ltd. ISBN 1 89845235 0.
- Chang, J.J.; Shinohara, K.; Hovey, R.M.; Montgomery, C. and Presti, J.C.Jr. (1998):**
Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. *Urol.*, 52: 89-93.
- Chen, M.E.; Troncoso, P.; Johanston, D.A. et al. (1997):**
Optimization of prostate biopsy strategy using computer based analysis. *J. Urol.*, 158: 2168-2175
- Chodak, G.W.; Keller, P. and Schoenber, H.W. (1989):**
Assessment of screening for prostate cancer using the digital rectal examination. *J. Urol.*, 141: 1136-8.
- Christensson, A.; Bjork, T.; Nilsson, O. et al. (1993):**
Serum prostate specific antigen complexed to alpha1-anti-chemotrypsin as an indicator of prostate cancer. *J. Urol.*, 150: 100.
- Chyou, R.H.; Nomura, A.M.Y. and Stemmermann, G.N. (1994):**
A prospective study of weight, body mass index and other anthropometric measurements in relation to site-specific cancers. In. *J. Cancer*; 98 (5): 385-398.

Clark LC, Combs GF Jr, Turnbull BW, et al, (1996):

Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group; JAMA;276:1957

Clark, T.W.; Goldenberg, L.; Cooperberg, P.L.; Wong, A.D. and Singer, J. (1997):

Stratification of prostate specific antigen level and results of transrectal ultrasonography and digital rectal examination as predictors of positive prostate biopsy. Can. Assoc. Radiol, 48 (4): 252-8.

Clement, J. and Makhtar, A. (1994):

Glandular kallikrein and prostate specific antigen are expressed in the human endometrium. J. Clin. Endocrin. Metab., 78: 1536-39.

Clinton, S.K. and Giovannucci, E. (1998):

Diet nutrition, and prostate cancer (Review). Annual Review of Nutrition, 18: 413-440.

Clinton, S.K.; Emenhiser, C.; Schwartz, S.; Bostwick, D.G.; Williams, A.W.; Moore, B.J. et al. (1996):

Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate; Cancer Epidemiol Biomarkers Prev;5:823.quoted from **Miller, E.C.; Giovannucci, E. and Erdman, J.W. (2002):**Tomato products, lycopene, and prostate cancer risk. Urol Clin N Am ;29 : 83-93

Coetzee, G.A. and Ross, R.K. (1994):

Prostate cancer and the androgen receptor. J. Natl. Cancer Inst.; 86 (11): 872-873.

Colditz, G. (1996):

Consensus conference: smoking and prostate cancer. Cancer Causes Control;7:560-2.

Coley, C.M.; Barry, M.J.; Fleming, C. et al. (1995):

Should Medicare provide reimbursement for prostate specific antigen testing for early detection of prostate cancer? II. Early detection strategies. Urology 46 (2): 125-141.

- Coley, C.M.; Barry, M.J.; Fleming, C. . and Mulley, A.G. (1997):**
Early detection of prostate cancer: I. Prior probability and effectiveness of tests. *Ann Internal. Med.*, 126: 394-406.
- Cookson, M.S. (2001):**
Prostate cancer: screening and early detection..*Cancer Control*; 8 (2): 133-140 .
- Cooner, W.H. (1990):**
Anatomy of the prostate as seen by ultrasound.
AUA Update Series, 9: 42.
- Cooner, W.H.; Mosley, B.R.; Rutherford, C.L. Jr. et al. (1991):**
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. *J Urol*;143:1146.
- Cooner, W.H.; Mosley, B.R.; Rutherford, C.L. et al. (2002):**
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. *J. Urol.*, 167: 966-974.
- Corder, E.H.; Guess, H.A.; Hulka, B.S. et al. (1993):**
Vitamin D and prostate cancer: A prediagnostic study with stored sera cancer epidemiology, Biomarkers and Prevention, 2: 467-472.
- Crawford, E.D.; DeAntoni, E.P.; Etzioni, R. et al. (1996):**
Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The prostate cancer education council. *Urology*, 47: 863-869.
- Criffith, J.C. (1980):**
Prostate-specific acid phosphatase: Re evaluation of radioimmunoassay in diagnosing prostatic disease. *Clin. Chem.*, 26: 99.
- Critz, F.; Williams, W.; Holladay, C. et al. (1999):**
Post-treatment PSA 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. *Urology*; 54:968-971..

- Crundwell, M.C, Cooke, P.W, and Wallace, D.M.A. (1999):**
Patient' tolerance of transrectal ultrasound-guided prostatic biopsy:an audit of 104 cases. BJU international;83:792-795.
- D'Amico, A.V.; Crook, J.; Bread, C.J.; DeWeese, T.L.; Hurwitz, M. and Kalan, I. (2002):**
Radiation therapy for prostate cancer. In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), Campbell's Urology, 8th ed. Saunders Company.
- Dall'era, M.A. and Evans, C.P. (2002):**
Tumor marker. In: Carroll, P.R. and Grossfeld, G.D. (eds), Atlas of Clinical Oncology (Prostate cancer) by American Cancer Society BC Decker Inc. Hanilton. London. ISBN 1-55009-130-1.
- Deliveliotis, C.; Alivizatos, G.; Starropoulos, N.J. et al. (1994):**
Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen. Urol. Int., 53: 186.
- DeWalf, W.C. (1996):**
Malignancy: underlying concepts of natural history, etiology and treatment. In Gillenwater, J.Y., Grayhack, J.T., Howards, S.S. and Duckett, J.W. (eds), Adults and Pediatric Urology, 3rd edition Mosby-Year Book, Inc.
- Djavan, B.; Marberger, M.; Zlotta, A. and Schulman, C.C. (1998):**
PSA, f/t-PSA, PSAD, PSA-TZ, and PSA-velocity for prostate cancer prediction: a multivariate analysis . J Urol. 159 (2):235.
- Djavan, B.; Zlotta, A.; Kratzik, C. et al. (1999):**
PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology, 54 (3): 517-522.
- Eastham, J.A. and Scardino, P.T. (2002):**
Radical prostatectomy. In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), Campbell's Urology, 8th ed. Saunders Company.

Egan, A.J. and Bostwick, D.G. (1997):

Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: Perineural invasion lacks significance on multivariate analysis. *Am J Surg Pathol* ; 21:1496–1500.

Egawa, S.; Wheeler, T.M.; Greene, D.R. and Scardino, P.T. (1992):

Unusual hyperechoic appearance of prostate cancer on transrectal ultrasonography. *Br J Urol.*; 69:169–74.

Ekman, P.; Barrack, E.R.; Greene, G.L.; Jensen, E.V. and Walsh, P.C. (1983):

Estrogen receptors in human prostate: Evidence for multiple binding sites. *J. Clin. Endocrin. Metab.*, 57: 166-176 quoted from *Stanford, J.L.; Damber, J.E.; Fair, W.R. et al. (1999):* Epidemiology of prostate cancer. In: Murphy, G.; Khoury, S.; Partin, A. and Denis, L. (eds): *Prostate cancer (2nd International Consultation on Prostate Cancer. June. 27-29, Paris, Health Publication. Ltd. ISBN 1 89845235 0.*

Ellis, W.J.; Chentner, M.P.; Preston, S.D. and Brawer, M.K. (1994):

Diagnosis of prostatic carcinoma. The yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. *J. Urol.*, 152: 1520.

Enlund, A.L. and Varenhorst, E. (1997):

Morbidity of ultrasound guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases. *Br. J. Urol.*, 79: 777-780.

Epstein, J.I. (1998):

The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer. *Semin Urol. Oncol* 1998;16:124–128.

Epstein, J.I.(2002):

Pathology of prostatic neoplasia, In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), *Campbell's Urology*, 8th ed. Saunders Company

Epstein, J.I. and Wojno, K.J. (1999):

The prostate and seminal vesicles. In Sternberg SS ed. Diagnostic Surgical Pathology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins:1893-942.

Epstein, J.I.; Walsh, P.C.; Carmichael, M. and Biendlic, C.B. (1994):

Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA, 271: 368-74.

Epstein JI, Grignon DJ, Humphrey PA, et al : .(1995):

Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 19: 873-86.

Epstein, J.I.; Partin, A.W.; Sauvageot, J. and Walsh, P.C. (1996):

Prediction of progression following radical prostatectomy . Am J Surg Pathol 20: 286-92.

Epstein, J.I.; Walsh, P.C.; Sauvageot, J. et al. (1997):

Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J. Urol., 158: 1886-1890.

Eskew, L.A.; Bare, R.L. and McCullough, D.L. (1997):

Systematic 5 region prostate biopsy is superior to sextant method for diagnostic carcinoma of the prostate. J. Urol., 157: 199-203.

Etzioni, R.; Penson, D.F.; Legler, J.M.; Tommaso, D.; Boer, R.; Gann, D.H. and Fever, E.J. (2002):

Over diagnosis due to PSA screening: Lessons from U.S prostate cancer incidence trends. J. Nat. Can. Inst. Vol. 94, No. 13, July 3.

Ferguson, R.S. (1930):

Prostatic neoplasm: Their diagnosis by needle puncture and aspiration. Am. J. Surg., 9: 507. quoted from Applewhite, J.C.; Matlaag, B.R.; McCullough, D.L. and Hall, M.C. (2001): Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. Cancer Control., 8: 141-150.

Ferreira, M.D. and Koff, W.J. (2005):

Assessment of serum level of prostate specific antigen adjusted for the transition zone volume in early detection of prostate cancer. Inter. Braz. J. Urol., 31 (2): 137-146,

Finne, P.; Zhang, W.; Auvinen, A. Et al. (2000):

Use of the complex between prostate specific antigen and alpha1-protease inhibitor for screening prostate cancer. J. Urol., 164: 1956-60.

Fleshner, N.E. (2002):

Vitamin E and prostate cancer. Urol. Clin. N. Am.; 29: 107-113.

Fleshner, N.E. and Fair, W.R. (1997):

Indications for transition zone biopsy in the detection of prostatic carcinoma. J. Urol., 157: 556-558.

Fogarty, K.T.; Arger, P.H.; Shibutani, Y. et al. (1994):

Follow-up of benign Hypoechoic Peripheral Zone Lesions of the Prostate Gland: US Characteristics and Cancer Prevalence' Radiology; 191 :69-74

Fowler, G. and Austoker, J. (1997):

Screening. The practice of public health. In: Holl R.W.W.; McEwen, J. and Omenn, G.S (eds), Oxford text book of public health, 3rd ed. Vol. 3, New York, Oxford Tokyo, Oxford University Press.

Friedman, G.G.; Hiatt, R.A.; Quesenberry, C.P.J. and Selby, J.V. (1999):

Case-control study of screening for prostate cancer by digital rectal examination. Lancet, 337: 1526-29.

Gann, P.H.; Hennekens, C.H.; MA, J.; Longcope, C. and Stampfer, M.J. (1996 a):

Prospective study of sex hormone levels and risk of prostate cancer J. Natl. Cancer Inst., 88 (16): 1118-1126.

Gann, P.H.; Ma, J.; Hennekens, C.H. et al. (1996 b):

Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiology, Biomarker and Prevention; 5: 121-126.

Gao, H.; Li, Y.; Wu, S. et al. (2005):

Mass screening of prostate cancer in a chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J. Androl., 7 (2): 159-163

- Gavin, A.; Maccarron, P.; Middleton, R.J. et al. (2004):**
Evidence of prostate cancer screening in a UK region.
BJU International, 93: 730-734.
- Giovannucci, E. (1999):**
Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst ;91:317.
- Giovannucci, E.; Rimm, E.B.; Colditz, G.A. et al. (1993):**
A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer. Inst., 85: 1571-79.
- Giovannucci, E.; Ascherio, A.; Rimm, E. and Wingo, P.A. (1995):**
Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst ;87: 1767.
- Giovannucci, E.; Rimm, E.B.; Wolk, A.; Ascherio, A.; Stampfer, M.J.; Colditz, G.A. and Willett, W.C. (1998):**
Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res., 58 (33): 442-447.
- Graves, H.C.; Wehner, N. And Stamey, T.A. (1992):**
Ultrasensitive radioimmunoassay of prostate specific antigen. Clin. Chem., 38: 735-742.
- Grayhack, J.T.; McVary, K.T. and Kozlowski, J.M (2002):**
Benign Prostatic Hyperplasia, In: Gillenwater, J.Y , Grayhack, J.T, Howards, S.S. and Mitchell, M.E, (eds) , Adult and Pediatric Urology 4th edition , Lippincott Williams & Wilkins
- Greene, D.R.; Shahsigh, R. and Scardino, P.T. (1992):**
Urologic ultrasonography. In Walsh, P.C.; Retik, A.B., Stamey, T.A., Vaughan, E.D Jr. (Eds): Campbell's Urology, 6th ed. Philadelphia, W.B. Saunders Company, PP. 342
- Greenlee, R.T.; Murray, T.; Bolden, S. et al. (2000):**
Cancer statistics, CA cancer J. Clin. 50 : 15-36.
- Greenlee, R.T.; Hill-Harmon, M.B. and Thun, M. (2001):**
Cancer statistics. CA cancer J. Clin. 51: 36.

- Gretzer, M.B. and Partin, A.W. (2003):**
PSA markers in prostate cancer detection.
Urol. Clin. N. Am., 30: 677-686.
- Grimberg, A. and Cohen, P. (2000):**
Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol., 183: 1.
- Gromley, G.J.; Stoner, E.; Bruskewitz, R.C. et al. (1992):**
The effect of finasteride in men with benign prostatic hyperplasia.
N. Eng. J. Med., 327: 1185-1191.
- Grönberg, H.; Damber, L.; Damber, J.E. and Iselius, L. (1997):**
Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance. Am. J. Epidemiol., 146 (7): 552-557.
- Guess, H.A.; Heyze, J.F. and Gromley, G.J. (1993):**
The effect of finasteride on prostate specific antigen in men with benign prostatic hyperplasia. Prostate, 22: 31-37.
- Gupta, S. and Mukhtar, H. (2002):**
Green tea and prostate cancer. Urol Clin N Am ;29 : 49-57
- Gunha, G.R.; Dongacour, A.A.; Cooke, P.S.; Mee, S.; Higgins, S.J. and Sugimura, Y. (1987):**
The endocrinology and developmental biology of the prostate. Enocrine Soc., 8 (3): 338-362. Quoted from **Stanford, J.L.; Damber, J.E.; Fair, W.R. et al. (1999):** Epidemiology of prostate cancer. In: Murphy, G.; Khoury, S.; Partin, A. and Denis, L. (eds): Prostate cancer (2nd International Consultation on Prostate Cancer. June. 27-29, Paris, Health Publication. Ltd. ISBN 1 89845235 0.
- Gustafsson, O.; Mansour, E.; Norming, U.; Carlsson, A.; Tomblom, M. and Nyman, C.R. (1998):**
PSA density and age-adjusted PSA reference values in screening for prostate cancer-a study of a randomly selected population of 2,4000 men. Scand. J. Urol. Nephrol., 32: 373-7.

Hagood, P.G.; Parra, R.O. and Rauscher, J.A. (1994):

Non traumatic election of prostate-specific antigen following cardiac surgery and extra-corporeal cardiopulmonary bypass. J. Urol., 152: 2043.

Halpern, E.J.; Verkh, L.; Forsberg, F.; Gomella, L.G.; Mattrey, R.F. and Goldberg, B.B. (2000):

Initial experience with contrast enhanced sonography of the prostate. Am. J. Roenternol., 174: 1575-80.

Hamper, U.M.; Sheth, S.; Walsh, P.C. and Epstein, J.I. (1990):

Bright echogenic foci in early prostatic carcinoma: Sonographic and pathologic correlation. Radiology;176:339-343

Hamper, U.M.; Trapanotto, V.; Dejong, M.R.; Sneth, S. and Caskey, C.L. (1999):

Three dimensional US of the prostate: early experience. Radiology, 212: 719-23.

Han, M. and Partin, A.W. (2001):

The role of free PSA (prostate specific antigen) and hk-2 (Human kallikrein-2) in prostate cancer detection. AUA update series;20 lesson 10 :73-80..

Han, M.; Snow, P.B; Epstein, J.I. et al. (2000):

A neural network predicts progression for men with Gleason score 3+7 versus 4+3 tumours after radical prostatectomy. Urology 56: 994.

Hankey, B.F.; Feuer, E.J.; Clegg, L.X. et al. (1999):

Cancer surveillance series: interpreting trend in prostate cancer. Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates. J. Nalt. Cancer. Inst., 91: 1017.

Hara, M.; Innove, T. and Fukoyama, T. (1971):

Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Japanese J. Legal. Med., 25: 322,quoted from appraisal of estimating both free and total PSA for diagnosis of cancer prostate,MD.thesis by Wleed Mohamed Elboushy .faculty of medicine ,urology department ,Cairo university,2001.

- Harris, R.P.; Lohr, K.N.; Beck, R.; Finkk, Grodley, P. and Buntor, A. (2001):*
Screening for prostate cancer. Systemic Evidence Review No 16 (Prepared by the Research Triangle Insitute-University of North Carolina Evidence-based practice Center under Contract No. 290-97-0011). Rockville, MD: Agency for Healthcare Research and Quality. (Available on the AHRQ Web site www.ahrq.gov/clinic/serfiles.htm).
- Hasui, Y.; Marutsuka, K.; Asada, Y. et al. (1994):*
Relationship between serum prostate-specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. *Prostate*, 25: 91.
- Hayes, R.B.; DeJong, F.H.; Raatgener, J. et al. (1992):*
Physical characteristics and factors related to sexual develop nent and behaviour and the risk of prostatic cancer. *Eur. J. Cancer Prev.*, 1 (3): 239-245.
- Heman-Ackah, C.A.; Festenstein, J.B.; Hibbert, P. et al. (1997):*
Experience with an assay for prostate-specific antigen and transrectal ultrasonography in the diagnosis of prostate cancer. *Br. J. Urol.*, 79 (3): 439-444.
- Hodge, K.K.; McNeal, J.E. and Stamey, T.A. (1989):*
Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. *J. Urol.*, 142: 66-70.
- Honda, G.D.; Bernstein, L.; Ross, R.K. et al. (1988):*
Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men. *Br. J. Cancer*, 57 (3): 326-331.
- Hsing, A.W. and Comstock, G.W. (1993):*
Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. *Cancer Epidemiol. Biom. Prev.*, 2 (1): 27-32
- Hudson, M.A. (1996):*
Screening for Prostate Cancer, AUA update series; 15, lesson. 25: 197-204

Hugosson, J.; Aus, G.; Bergdahl, S. et al. (2003):

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU. International, 92, Supplement 2: 39-43.

Ishimura, I.; Sakai, I.; Eto, H. And Miyake, H. (2004):

Clinical outcome of transrectal ultrasound-guided prostate biopsy, targeting eight cores, for detecting prostate cancer in Japanese men. Int. J. Clin. Oncol, 9 (1): 47-50.

Jacobsen, S.J.; Bergstahl, B.J.; Katusic, K. et al. (1998):

Screening digital rectal examination and prostate cancer mortality, a population based case-control study. Urol., 52: 173-179.

Kabalin, J.N. (1993):

Urolane laser prostatectomy, monographs. Urology, 14: 23-36.

Karakiewicz, P.I.; Bazinet, M.; Aprikian, A.G. et al. (1996):

Value of systematic transition zone biopsies in the early detection of prostate cancer. J. Urol., 155: 605-606.

Katz, D.A.; Mchorney, C.A. and Schapira, M.M. (1998):

Health quality of life in men with localized prostate cancer. J. Gen. Intern. Med., 13 (Supl.): 16-24.

Kaye, K.W. (1991):

Ultrasound of the normal prostate. Contemporary Urology 3: 64.

Kaye, K.W. and Richter, U. (1990):

Ultrasonographic anatomy of normal prostate gland: Reconstructive by Computer graphics. Urol., 35: 12.

Keetch, D.W. and Catalona, W.J. (1995):

Prostatic transition zone biopsies in men with previous negative previous biopsies and persistently elevated serum prostatic specific antigen values. J. Urol., 154: 1795-1797.

Kessler, B.; Albertsen, P. (2003):

The natural history of prostate cancer. Urol. Clin. N. Am., 30: 219-226.

- Khan, H.; Khan, F. and Yusof, S. (2003):**
Prostate cancer screening: McMaster Univ. Med. J. (MUMJ); 1 (1): 20-26.
- Kim, J.H.; Chang, S.G. and Kim, Y.W. (2000):**
Pathological diagnosis and clinical finding in patient undergoing transrectal prostatic biopsy. Korean J. Urol., 43: 1408 (Abstract).
- Kirkali, Z.; Kirkali, G. and Esen, A. (1995):**
Effect of ejaculation on prostate specific antigen levels in normal men. Eur. Urol., 27:292.
- Klomp, M.L.F.; Hendrikx, A.J.M. and Keyzer, J.J. (1994):**
The effect of transrectal ultrasonography (TRUS) including digital rectal examination (DRE) of the prostate on the level of PSA. BJU, 73: 41-74.
- Kolonel, L.N.; Nomura, A.M.Y and Coone, R.V. (1999):**
Dietary fat and prostate cancer: current status. J. Natl Cancer. Inst., 91: 414-428.
- Kozlowski, J.M. and Grayhack, J.T. (2002):**
Carcinoma of the prostate. In: Gillenwater J.Y, Grayhack, J.T.; Howards, S.S. and Mitchell, M.E. (Eds). Adults and Pediatric Urology, 4th edition Lippincott Williams and Wilkins.
- Kramer, B.S.; Brower, M.I.; Prorok, P.C.; Potosky, A.L. and Gohagen, J.K. (1994):**
Prostate cancer screening: what we known and what we need to known. Ann. Intern. Med., 119: 914-923.
- Kristal, A.R.; Stanford, J.L; Cohen, J.H. et al. (1999):**
Vitamin and mineral supplement use is associated with reduced Risk of prostate cancer; Cancer Epidemiol Biomarkers Prev; 8:887-92.
- Kuligowska, E.; Barish, M.A.; Fenlon, H.M. and Blake, M. (2001):**
Predictors of prostate carcinoma: Accuracy of gray-scale and color Doppler US and serum markers. Radiol., 220: 757-764.

- Kuman, A.; Mikolajczyk, S.D.; Goel, A.S.; Millar, L.S. and Saedi, M. (1997):**
Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein2. *Cancer Res.*, 57: 3111-14.
- Kwak, G.; Jeong, S.J.; Park, M.S.; Lee, P.E. and Lee, S.E. (2002):**
Prognostic significance of the nadvi prostate specific antigen level after hormone therapy for prostate cancer. *J. Urol.*, 168: 995-1000.
- Kwiatkowski, M.; Huber, A.; Moscobulos, M.; Lebmann, K.; Wernli, M.; Hafeli, A. and Recker, F. (2004):**
Screening for prostate cancer: Results of a prospective trial in canton Aargau, Switzerland. *Swiss Med. Wkly*, 134: 580-585.
- Labrie, F.; Candas, B.; Dupout, A. et al. (1999):**
Screening decrease prostate cancer death: First analysis of the 1988 Quebec. prospective randomized control trial. *Prostate*: 38: 83-91.
- Lannin, T.; Franklin, C. et al. (1997):**
The effect of prostatic manipulation of PSA level. *Urol. Clin. N. Am.*, 24: 295.
- Lattouf, J. and Saad, F. (2003):**
Digital rectal examination following prostatectomy: Is it still necessary with the use of PSA? *Europ. Urol.*, 43: 333.
- Lau, W.K.; Blute, M.L.; Bostwick, D.G. et al. (2001):**
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. *J Urol* 166: 1692-7.
- Lee, F.; Gray, J.M.; McLeary, R.D. et al. (1985):**
Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology and staging. *Prostate*, 7: 117-119.
- Lee, F.; Gray, J.M.; McLeary, R.D. et al. (1989):**
Transrectal ultrasound in the diagnosis and staging of prostate carcinoma. *Radiology*, 170: 609-615.
- Levesque, M.A.; Yu, H.; D'Costa, M. et al. (1995):**
Prostate specific antigen expression by various tumors. *J. Clin. Lab. Anal.*, 9: 123-128.

- Levine, M.A.; Ittman, M.; Melamed, J. and Loper, H. (1998):**
Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J. Urol., 159: 471-475.
- Lilja, H.; Christensson, A.; Dahlen, U.; Matikainen, M.T.; Nilsson, O.; Pettersson, K. et al. (1991):**
Prostate-specific antigen in serum occurs predominantly in complex with alpha1-antichymotrypsin. Clin. Chem., 37 (9): 1618-25.
- Lindert, K.A.; Kabalin, J.N. and Terris, M.K. (2000):**
Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J. Urol., 164: 76-80.
- Ludwig, M.; Weidner, W.; Schroeder and Printzen, I. (2000):**
Transrectal prostatic sonography as a useful diagnostic tool. J. Urol., 163: 172-173.
- Lui, P.D.; Terris, M.K.; McNeal, J.E. et al. (1995):**
Indication for ultrasound guided transition zone biopsies in the detection of prostate cancer. J. Urol., 153: 1000-1003.
- Lumey, L.H. (1996):**
Prostate cancer and smoking: a review of case-control and cohort studies. Prostate;29:249-60
- Matchariyakul, C.; Kochakarn, W.; Chaimuangrag, S. et al. (2004):**
A risk index for prostate cancer. Int. J. Urol., 11: 310-315.
- Mayewski, R.J.; Mushlin, A.I. and Griner, P.F. (1986):**
Principles of test selection and use: Clinical diagnosis and the laboratory (eds: Griner, P.F.; Panzer, R.J.; Greenland, P.). Chap.I, PP 1-15. London:Year Book Medical Publishers, INC
- McNeal, J.E. (1988):**
Normal histology of the prostate. Am. J. Surg. Pathol., 1988;12:619
- McNeal, J.E.; Villers, A.A.; Redwine, E.A. et al. (1990):**
Capsular penetration in prostate cancer. Am. J. Surg. Pathol., 14: 240-7.

- Merrill, R.M.; Feuer, E.J.; Warren, J.L.; Schussler, N. and Stephenson, R.A. (1999):**
Role of transurethral resection of the prostate in population based prostate cancer incidence rates. *Am. J. Epidemiol.*, 150: 848-60.
- Meux, M.D.; Gotawy, M.B. and Coakley, F.V. (2002):**
Imaging. In: Carroll, P.R. and Grossfeld, G.D. (eds), *Atlas of Clinical Oncology (Prostate cancer)* by American Cancer Society BC Decker Inc. Hanilton. London. ISBN 1-55009-130-1.
- Miller, E.C.; Giovannucci, E. and Erdman, J.W. (2002):**
Tomato products, lycopene, and prostate cancer risk.
Urol Clin N Am ;29 : 83-93
- Mistry, K. and Cable, G. (2003):**
Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. *J. Am. Board of Family Medicine*, 16 (2): 95-101.
- Mokhtar, N. (1991):**
Cancer Pathology Registry, NCI, Al-Asdekaa Press, Cairo, Egypt,.
quoted from (The Prognostic Significance of CD44, p21 and MIB-1 in Cancer Prostate) MD thesis by Nashwa M. Emara, Pathology Department, Benha Faculty of Medicine.2003
- Monne, M.; Croce, C.M.; Yu, H. et al. (1994):**
Molecular characterization of prostate specific antigen messenger RNA expressed in breast tumors cancer. *Res.*, 45: 6344-47.
- Montironi, R. and Schulman, C.C. (1996):**
Precursors of prostatic cancer: progression, regression and chemoprevention ; *Eur Urol* 30: 133-7.
- Morgan, T.O.; Jacobsen, S.J.; McCarthy, W.F. et al. (1996):**
Age-specific reference ranges for prostate-specific antigen in black men. *N Engl J Med*;335:304.
- National Cancer Institutes (2002):**
Surveillance, Epeidemiology, and End results (SEER) program public-Use Data (1973-1998). Available at: <http://seer.cancer.gov>.

- Nielsen, C. and Lang, R.S. (1999):**
Principles of screening. *Med. Clin. N. Am.*, 83: 1323-1338.
- Noldus, J. and Stamey, T.A. (1996):**
Histological characteristics of radical prostatectomy specimens in men with serum prostatic specific antigen of 4 ng/ml or less
J. Urol., 155: 441-3.
- Noldus, J.; Graefen, M.; Huland, E. et al. (1998):**
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. *J. Urol.*, 159: 2004.
- Nomura, A.; Heilbrun, L.K.; Stemmermann, G.N. and Judd, H.L. (1988):**
Prediagnostic serum hormones and the risk of prostate cancer. *Cancer Res.*, 48 (12): 3315-3517.
- Norrish, A.E.; Ferguson, L.R. and Knize, M.G. et al. (1999):**
Heterocyclic amine content of cooked meat and risk of prostate cancer. *J. Natl. Cancer. Inst.*, 91: 2038-44.
- Oliver, S.E.; Gunnell, D. and Donovan, J.L. (2000):**
Comparison of trends in prostate cancer mortality in England and Wales and the USA. *Lancet*, 355: 1788-9.
- Osterling, J.E. (1991):**
Prostate antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. *J. Urol.*, 145: 907.
- Osterling, J.E.; Jacobson, S.J.; Chut, C.G. et al. (1993):**
Serum prostate-specific antigen level in men with and without prostate disease. *JAMA*, 267: 2215-2220.
- Osterling, J.E.; Jacobsen, S.J.; Klee, G.G. et al. (1995):**
Free, complexed, and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. *J. Urol.*, 154: 1022-1027.
- Papotti, M.; Paties, C.; Peveri, V. et al. (1989):**
Immunocytochemical detection of prostate specific antigen in skin adnex and breast tissue and tumors. *Basic Applied Histochemistry*, 38: 25-29.

- Papsidero, L.D.; Wang, M.C.; Valenzuela, L.A. et al. (1980):**
A prostate antigen in sera of prostatic cancer patient.
Cancer Res., 40: 2428.
- Park, S.; Miyake, H.; Hara, I. and Eto, H. (2003):**
Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int. J. Urol., 10: 68-71.
- Patrik, F.; Wan-Ming, Z.; Anssi, A. et al. (2000):**
Use of the complex between prostate specific antigen and alpha-1-protease inhibitor for screening prostate cancer. J. Urol. 164: 1956-1960.
- Peehl, D.M.; Cohen, P. and Rosenfeld, R.G. (1996):**
The role of insulin-like growth factors in prostate biology.
J. Androl., 17: 2.
- Philip, J.; Roy, S.D.; Ballal, M.; Foster, C.S. and Javle, P. (2005):**
Is digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer. BJU International, 95: 969-971.
- Polascik, T.J.; Oesterling, J.E. and Partin, A.W. (1999):**
Prostate specific antigen: A decade of discovery-what we have learned and where are going? J. Urol., 162: 1293.
- Post, P.N.; Kil, P.J. and Coebergh, J.W. (1999):**
Trends in survival of prostate cancer in south eastern Netherland, 1971-1989. Int. J. Cancer, 81: 551.
- Prehn, R.T. (1999):**
On the prevention and therapy of prostate cancer by androgen administration. Cancer Res., 59: 4161.
- Punglia, R.S., D'Amico, A.V., Catalona, W.J., Roehl, K.A. and Kuntz, K.M. (2003)**
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen N Engl J Med ;349:335-42.
- Radge, H.; Aldapa, H.C. and Bagley, C.M.Jr. (1988):**
Ultrasound-guided prostate biopsy. Biopsy gun superior to aspiration. Urology, 32: 503-506.

- Randolf, T.L.; Amin, M.B.; Ro, J.Y. and Ayala, A.G. (1997):**
Histological variants of adenocarcinomas of the prostate: pathological criteria and clinical significance. *Mod Pathol* 10: 612.
- Raviv, G.; Janssen, T.H.; Zlotta, A.R. et al. (1996):**
Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. *J Urol* 156:1050-5,
- Reiter, R.E. and Dekernion, J.B. (2002):**
Epidemiology, etiology and prevention of prostate cancer. In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), *Campbell's Urology*, 8th ed. Saunders Company.
- Riegman, P.H.; Vlietstra, R.J.; Van der Korput, J. et al. (1991):**
The promotor of the prostate specific antigen a gene contains a functional androgen responsive element *Mol. Endocrinal*, 5: 1921-30.
- Rietbergen, J.B.; Kranse, R.; Kirkels, W.J.; Dekong, H.J. and Schroder, F.H. (1997):**
Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection. *BJU*, 79 (suppl. 2: 57-63.
- Rietbergen, J.B.; Robert, F.; Arto, E.H.; Kruger, B.; Kirkels, W.J. and Schroder, F.H. (1999):**
The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screen study. *J. Urol.*, 161: 1192-98
- Rifkin, M.D.; Gay, S. and Saudakoff, M. (1993):**
Prostate: technique results and potential applications of color Doppler U.S. scanning. *Radiology*, 186: 509-513.
- Rodriguez, L.V. and Terris, M.K. (1998):**
Risks and complications of transrectal ultrasound guided prostate needle biopsy: A prospective study and review of the literature. *J. Urol.*, 160: 2115-2120.

- Rogers, R.S.; Carroll, P.R. and Tanagho, E. (2002):**
Anatomy. In: Carroll, P.R. and Grossfeld, G.D. (eds), Atlas of Clinical Oncology (Prostate cancer) by American Cancer Society BC Decker Inc. Hanilton. London. ISBN 1-55009-130-1.
- Rosenthal, M.A.; Taneja, S. and Bosland, M.C. (1998):**
Phytoestrogen and prostate cancer. Prostate preventive role. Med. J. Aust., 168: 467. Quoted from **Reiter, R.E. and Dekernion, J.B. (2002):** Epidemiology, etiology and prevention of prostate cancer. In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), Campbell's Urology, 8th ed. Saunders Company.
- Ross, R.K.; Shimizu, H.; Paganini-Hill, A.; Honda, G. and Henderson, B.E. (1987):**
Case-control studies of prostate cancer in blacks and whites in southern California. J. Natl. Can. Inst., 78 (5): 869-874.
- Ross, K.S.; Carter, H.B.; Pearson, J.D. and Guess, H.A. (2000):**
Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA, 284 (11):1399-405
- Salomon, L.; Colombel, M.; Patard, J.J.; Belots, Chopin, D.K. and Abbou, C.C. (1998):**
Use of three additional mid biopsies to improve local assessment of prostate cancer in patients with one positive sextant biopsy. Eur. Urol., 34: 313-7.
- Sandblom, G.; Dufmats, M.; Nordenskjold, K.; Varenhorst, E. (2000):**
Prostate carcinoma trends in three countries in Sweden 1987-1996: Results from a population based national cancer register. South-East Region Prostate Cancer Group. Cancer 88: 1445.
- Sauter, E.R.; Daly, M.; Lenahan, K. et al. (1996):**
Prostate specific antigen in nipple aspirate fluid correlate with breast cancer risk, Proc. American Association for Cancer Research, 37: 213, (Abstract).
- Seaman, E.; Whang, M.; Olsson, C.A. et al. (1993):**
Prostate-specific antigen density (PSAD): Role in patient evaluation and management. Urol Clin North Am;20:653.

- Selley, S.; Donovan, J.; Faulkner, A.; Coast, J. and Gillatt, D. (1997):**
Diagnosis management and screening of early localized prostate cancer. Health Technology Assessment. (HTA), 1 (2): 11 website (<http://www.Nchta.org>).
- Semjonow, A.; Roth, S. and Hamm, M. Re. (1995):**
Non traumatic elevation of prostate-specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass. J. Urol., 155: 295.
- Scattoni, V.; Roscigno, M.; Raber, M. et al. (2002):**
Role of ultrasonography-guided prostatic biopsy of hypoechoic areas associated with systemic biopsies in patients with normal and high PSA levels. Arch. Ital. Urol. Androl., 74 (4): 273-5 (Abstract).
- Schellhammer, P.F. and Wright, G.L. (1993):**
Biomolecular and clinical characteristics of PSA and other candidate tumor markers. Urol. Clin. N. Am., 597-606.
- Schröder, F.H. (2003):**
Screening for prostate cancer. Urol. Clin. N. Am., 30: 239-251.
- Schröder, F.H. and Kranse, R. (2003):**
Verification bias and the prostate-specific antigen test —is there a case for a lower threshold for biopsy? Editorials N Engl J Med. 349:393-5
- Schröder, F.H. and Wildhagen, M.F. (2001):**
Screening for prostate cancer: evidence and prospectives. BJU Int., 88: 811-17.
- Schröder, F.H.; Maa, P.; Beemsterboer, P.; Kruger, A.B. et al. (1998):**
Evaluation of the digital rectal examination as a screening test for prostate cancer. J. Natl Can. Inst., 90 (23): 1817-23
- Schröder, F.H.; Denis, L.J.; Roobol, M. et al. (2003):**
The story of the European randomized study of screening for prostate cancer. BJU International, 92 (Suppl. 2): 1-13.
- Seaman, E.; Whang, M.; Olsson, C.A. et al. (1993):**
Prostate-specific antigen density (PSAD): Role in patient evaluation and management. Urol Clin North Am;20:653.

Shepherd, D.; Keetch, D.W.; Humphrey, P. et al. (1996):

Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. *J Urol* 156:460-3.

Shinohara, K. and Carroll, P.R. (2002):

Cryotherapy for prostate cancer. In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), *Campbell's Urology*, 8th ed. Saunders Company.

Shinohara, K.; Wheeler, T.M. and Scardino, P.T. (1989):

The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. *J. Urol.*;142:76-82.

Smith, J.A. Jr. (1996):

Transrectal ultrasonography for the detection and staging of carcinoma of the prostate. *J. Clin. Ultrasound*, 24: 455-461.

Smith, D.S. and Catalona, W. (1995):

Inter examiner variability of digital rectal examination in detecting prostate cancer. *Urology*, 45: 70-74.

Smith MR and Kantoff PW. (2001):

Molecular Biology of Prostate Cancer. In Mendelsohn J, Howley PM, Israel MA, Liotta LA eds. *The molecular basis of cancer* 2nd ed. Philadelphia London New York: WB Saunders Company: 344 quoted from (The Prognostic Significance of CD44, p21 and MIB-1 in Cancer Prostate) MD thesis by Nashwa M. Emara, Pathology Department, Benha Faculty of Medicine.2003

Smith, R.A.; Cokkinides, V.; Von Eschenbach, A.C.; Levin, B.; Cohen, C.; Runowitz, C.D. et al. (2000):

American Cancer Society guidelines for early detection of prostate cancer. *CA Cancer J. Clin.*, 52: 8.

Sokoll, L.J.; Bruzek, D.J.; Cox, J.L. et al. (1998):

Is complexed PSA alone clinically useful? Part II. *J Urol*;159:234

- Song, J.M.; Kim, C.; Chung, H.C. and Kane, R.L. (2005):**
Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: A meta-analysis for this diagnostic trial of prostate cancer in symptomatic Korean men. *Yonsei. Med. J.*, 46 (3): 414-424.
- Spiro, L.H.; Laday, G. and Irkin, L.A. (1974):**
Prostate infarction: Role in acute urinary retention. *Urol.*, 3: 345, quoted from appraisal of estimating both free and total PSA for diagnosis of cancer prostate, MD.thesis by Wleed Mohamed Elboushy .faculty of medicine ,urology department ,Cairo university,2001.
- Spitz MR, Strom SS, Yamamura Y, et al. (2000):**
Epidemiologic determinants of clinically relevant prostate cancer. *Int J Cancer*; 89: 259-64.
- Stamey, T.A. (1995):**
Making the most out of six systematic sextant biopsies. *Urology*, 45: 2-12.
- Stamey, T.A.; Yang, N.; Hay, A.R.; McNeal, J.E.; Freiha, F.S. and Redwine, E. (1987):**
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *N. Engl. J. Med.*, 317 (15): 909-916.
- Stamey, T.A.; Kabalin, J.N.; Ferrar, M. et al. (1989):**
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: Anti-androgen treated patients. *J. Urol.*, 141: 1084.
- Stanford, J.L.; Damber, J.E.; Fair, W.R. et al. (1999):**
Epidemiology of prostate cancer. In: Murphy, G.; Khoury, S.; Partin, A. and Denis, L. (eds): *Prostate cancer (2nd International Consultation on Prostate Cancer)*. June. 27-29, Paris, Health Publication. Ltd. ISBN 1 89845235 0.
- Stenman, U.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K. and Alfthan, O. (1991):**
A complex between PSA and alpha1-antichymotrypsin is the major form of PSA in serum of patients with prostate cancer: Assay of the complex improves clinical sensitivity for cancer. *Cancer Research*, 51: 222.

Stephenson, R.A. (2002):

Prostate cancer trends in the era of prostate-specific. An update of incidence, mortality, and clinical factors from the SEER database. Urol. Clin. N. Am., 29: 173-181.

Stephenson, R.A.; Smart, C.R.; Meneau, G.P.; James, D.R. and Dibble, R.L. (1996):

The fall in incidence of prostate cancer: on the down side of a PSA induced peak in incidence. Cancer, 77: 1342-8.

Takahashi, H. and Ouchi, T. (1963):

The ultrasonic diagnosis in the field of urology. Proc. JPN. Ultrasonics Med., 3: 7. quoted from Applewhite, J.C.; Matlaag, B.R.; McCullough, D.L. and Hall, M.C. (2001): Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. Cancer Control., 8: 141-150.

Takayama, T.K.; Tisdale, E.; Bigler, S. et al. (1994):

Indication of seminal vesicle biopsy in the evaluation of prostate carcinoma. J. Urol., 151 (Supl.): 503

Takayama, T.K.; Fujikawa, K. and Davie, E.W. (1997):

Characterization of the precursor of prostate specific antigen. Activation by trypsin and by human glandular kollikrein. J. Biol. Chem., 272.

Tang, J, Li, S, and Yu, J. (2001):

Zhonghua Zhong Liu Za Zha, 23 (3): 228-9 (Abstract).

Tchetgen, M.B.; Song, J.T.; Strawderman, M. et al. (1996):

Ejaculation increases the serum prostate-specific antigen concentration. Urology, 47: 511.

Terris, M.K. (1999):

Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: Preliminary report. Urology, 50: 562-566.

Terris, M.K. (2000):

Extended field prostate biopsy: too much of a good thing? Urology, 55: 457-60.

Terris, M.K. (2002a):

Ultrasonography and biopsy of the prostate. In: Walsh, P.C., Retik, A.B., Vaughan E.D.Jr. and Wein, A.J. (eds), *Campbell's Urology*, 8th ed. Saunders Company.

Terris, M.K. (2002b):

Prostate biopsy strategies: past, present and future.
Urol. Clin. N. Am., 29: 205-212.

Terris, M.K.; McNeal, J.E. and Stamey, T.A. (1992):

Transrectal ultrasound imaging and ultrasound-guided prostate biopsies in the detection of residual carcinoma in clinical stage A carcinoma of the prostate. *J. Urol.*, 146: 864-869.

Terris, M.K.; Wallen, E. and Stamey, T.A. (1997a):

Routine performance of transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies is not indicated. *J. Urol.*, 157: 204-206.

Terris, M.K.; Wallen, E. and Stamey, T.A. (1997b):

Comparison of lateral versus mid-lobe systematic sextant biopsies in the detection of prostate cancer. *Urol. Inter.*, 59: 239-242.

Thune, I. and Lund, E. (1994):

Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norwegian men. *Cancer Causes Control*, 5: 549-556. Quoted from *Stanford, J.L.; Damber, J.E.; Fair, W.R. et al. (1999): Epidemiology of prostate cancer*. In: Murphy, G.; Khoury, S.; Partin, A. and Denis, L. (eds): *Prostate cancer (2nd International Consultation on Prostate Cancer)*. June. 27-29, Paris, Health Publication. Ltd. ISBN 1 89845235 0.

Tiguret R, Gheiler EL, Grignon DJ, et al. (2000):

Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors. *J Urol*;163:1486-90.

Timothy, R.R. (2002):

Inherited genotype and prostate cancer outcomes (Review) cancer epidemiology Biomarkers and prevention. Vol. 11, 945-952. October 2002.

- Tokunaga, M.; Yasada, M.; Mikiyaki, H. et al. (2005):**
Screening program of prostate cancer at Tokai University Hospital: Characterization of prostate-specific antigen measurement. Tokai J. Exp. Clin. Med., 30 (2): 103-10. (Abstract).
- Tsukamoto, T.; Kumamoto, Y.; Masumori, N. et al. (1995):**
Mass screening for prostate carcinoma: a study in Hokkaido, Japan Eur. Urol., 27: 177-81.
- Uchida, K.; Takeshima, H.; Akaza, H. and Ono, Y. (2000):**
Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: Results of the health checkup system. Japanese. J. Clin. Oncol., 30: 95-100.
- United States Preventive Services Task Force (USPSTF) (2002):**
Screening for prostate cancer: recommendations and Rationale Available at the (USPSTF) web site (www.Preventiveservices.ahrq.gov).
- Uzzo, R.G.; Wei, J.T.; Waldbaum, R.S. et al. (1995):**
The influence of prostate size on cancer detection. Urology;46:831.
- Van Der Crujisen-Koeter, I.W.; Wildhagen, M.F.; Dekoning, H.J. and Schroder, F.H. (2001):**
The value of current diagnostic tests in prostate cancer screening. BJU. International, 88: 458-466.
- Veierod, M.B.; Laake, P. and Thelle, D.J. (1997):**
Dietary fat intake and risk of prostate cancer: A prospective study of 25,708 Norwegian men. Int. J. Cancer, 73: 634-638.
- Vessella, R.L. and Lange, P.H. (1997):**
Issues in the assessment of prostate-specific antigens immunoassays. An update. Urol Clin North Am;24:261.
- Wang, M.C.; Valenzuela, L.A.; Murphy, G.P. et al. (1979):**
Purification of a human prostate specific antigen. Invest. Urol., 17: 159, quoted from Kozlowski, J.M. and Grayhack, J.T. (2002): Carcinoma of the prostate. In: Gillenwater J.Y, Grayhack, J.T.; Howards, S.S. and Mitchell, M.E. (Eds). Adults and Pediatric Urology, 4th edition Lippincott Williams and Wilkins.

Wang, M.C.; Papsidero, L.C.; Kuriyama, M. et al. (1981):

Prostatic antigen: A new potential marker for prostatic cancer.

Prostate 2: 89. quoted from appraisal of estimating both free and total PSA for diagnosis of cancer prostate, MD. thesis by Wleed Mohamed Elboushy .faculty of medicine ,urology département ,Cairo university, 2001.

Wang, T.J.; Hill, T.M.; Sokoloff, R. et al. (1996):

Dual monoclonal antibody immunoassay for free prostate-specific antigen .Prostate; 28: 10.

Watanabe, H.; Igari, D.; Tanahasi, Y. Et al. (1974):

Development and application of new equipment for transrectal ultrasonography. J. Clin. Ultrasound, 2: 91-98. quoted from Applewhite, J.C.; Matlaag, B.R.; McCullough, D.L. and Hall, M.C. (2001): Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. Cancer Control., 8: 141-150.

Waterhouse, R.L. and Resnick, M.I. (1989):

The use of transrectal prostatic ultrasonography in the evaluation of patients with prostatic carcinoma. J. Urol., 141: 233-239.

Westphale, J.; Heidenveich, A.; Zumb, J. and Engelmann, U.H. (1995):

The impact of ejaculation on serum PSA.
J. Urol., 153: 464.

Whitby, L.G.; Percy-Robb, I.W. and Smith, A.F. (1984):

Lecturer notes on clinical chemistry, 3rd edition, chap 1, PP.1-9
Oxford: Blackwell Scientific Publication.

Whitby, L.G.; Smith, A.F. and Beckett, G.J. (1988):

Clinical chemistry of pediatric: Lecturer notes on clinical chemistry, 4th edition, chap. 22, PP. 287-308.
Oxford: Blackwell Scientific Publication.

Wilbert, M.; Griffin, J.E. and Wilson, G.D. (1983):

Characterization of the cytosol androgen receptor of the human prostate. J. Clin. Endocrin. Metab., 56: 113-119. Quoted from **Stanford, J.L.; Damber, J.E.; Fair, W.R. et al. (1999):** Epidemiology of prostate cancer. In: Murphy, G.; Khoury, S.; Partin, A. and Denis, L. (eds): Prostate cancer (2nd International Consultation on Prostate Cancer. June. 27-29, Paris, Health Publication. Ltd. ISBN 1 89845235 0.

- Wilson, T.M. and Gburek, B.M. (1996):**
Transrectal ultrasonic guided prostate biopsy.
AUA update series, 15, Lesson 27: 214-219.
- Woodrum, D.L.; Brawer, M.K.; Partin, A.W.; Catalona, W.J. and Southwick, P.C. (1998):**
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J. Urol., 159 (1): 5-12.
- Woolf, S.H. (1995):**
Screening for prostate cancer with prostate-specific-antigen: An examination of the evidence. New Engl. Med. J. Med., 333: 140-5.
- World Health Organisation (WHO) .(2003) :**
Facts and Figures. The World Health Report 2003.
-Shaping the Future.
- Yao, S.L. and Lu-Yao, G. (2001):**
Interval after prostate-specific antigen testing and subsequent risk of incurable prostate cancer. J. Urol., 166 (3): 861-5.
- Yoshizawa K, Willett WC, Morris SJ, et al. (1998):**
Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer; J Natl Cancer Inst ;90:1219.
- Yu, H. and Diamandis, E.P. (1995):**
Prostate specific antigen immunoreactivity in amniotic fluid.
Clin. Chem., 41: 54-60.
- Yu, H.; Diamandis, E.P.; Levesque, M.A. et al. (1994):**
Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. J. Clin. Lab. Anal., 8: 253.
- Yu, H.; Giai, M.; Diamandis, E.P. et al. (1995):**
Prostate antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res., 55: 2104-10.
- Yuan, J.J.; Coplen, D.E.; Petros, J.A. et al. (1992):**
Effect of rectal examination, ultrasonography and needle biopsy on serum prostate specific antigen levels. J. Urol., 147: 810-814.

Yuen, J.S.P.; Lua, W.K.O.; Ng, L.C. et al. (2004):

Clinical biochemical and pathological features of initial and repeat transrectal ultrasonography prostate biopsy positive patients.

Int. J. Urol., 11: 225-231.

Zhou, J.R. and Blackburn, G.L. (1997):

Bridging animal and human studies: what are the missing segments in dietary fat and prostate cancer? .Am. J. Clin. Nutr.; 66: 15725.